Helping Caregivers



Parents or caregivers can learn about treating their child’s asthma with
PULMICORT RESPULES at www.pulmicortrespules.com, a site specifically designed for patients and caregivers. The site contains information about PULMICORT RESPULES, explains how the medicine works, shows how to administer it with a jet nebulizer, and explains how PULMICORT RESPULES can help control asthma symptoms in children from 12 months to 8 years of age.


Making asthma treatment a natural part of a child’s daily routine is important and does not have to be challenging. The following are just a few tips to share with your patients’ caregivers.

  • Suggest that parents do the treatment(s) at the same time each day, so that their child comes to expect it as a regular part of the daily routine
  • Encourage parents to entertain their child with videos, music, toys, coloring books, or puzzles, or to read to the child during treatment
  • Have parents put the mask on a favorite stuffed toy or doll first and show how much fun the toy is having or how brave it is — then have them transfer the mask to their child

IMPORTANT NOTES

  • It is important to make sure that parents are aware that they need to use a jet nebulizer if you have prescribed PULMICORT RESPULES for their child2
  • PULMICORT RESPULES should not be mixed with other nebulized medications, as the safety and effectiveness of doing so have not been adequately assessed2


IMPORTANT SAFETY INFORMATION ABOUT PULMICORT RESPULES


PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Particular care is needed for patients who are transferred from systemically active corticosteroids to PULMICORT RESPULES, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

It is possible that systemic corticosteroid effects such as hypercorticism, reduced bone mineral density, and adrenal suppression may appear in a small number of patients, particularly at higher doses.

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

Hypersensitivity reactions, including anaphylaxis, have been reported with budesonide.

As with other inhaled medications, paradoxical bronchospasm may occur with
PULMICORT RESPULES.

In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions and clinical features consistent with Churg-Strauss Syndrome.

Adverse reactions that occurred at a rate of ≥ 3% are: respiratory infection, rhinitis, coughing, otitis media, viral infection, moniliasis, gastroenteritis, vomiting, diarrhea, abdominal pain, ear infection, epistaxis, conjunctivitis, and rash.


Indication


PULMICORT RESPULES (budesonide inhalation suspension) is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

Please click here for full Prescribing Information for PULMICORT RESPULES.